Evidence map›Paper›PMID 38019182›Full record

ArticleLupus2024

Referral and evaluation for kidney transplantation among patients with lupus nephritis-related end-stage kidney disease.

Laura McPherson, Laura C Plantinga, Penelope P Howards, Michael Kramer, Stephen O Pastan, Rachel E Patzer

Open access · greenAbstract read
In one paragraph

Article in Lupus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Renal disease in pediatric rheumatology.Current opinion in rheumatology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Laura McPhersonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID 0000-0001-8135-1408
Laura C PlantingaDivisions of Rheumatology and Nephrology, Department of Medicine, University of California, San Francisco, CA, USA.
Penelope P HowardsDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Michael KramerDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Stephen O PastanDepartment of Medicine, Emory UniversitySchool of Medicine, Atlanta, GA, USA.
Rachel E PatzerDivision of Transplantation, Department of Surgery, Indiana UniversitySchool of Medicine, Indianapolis, IN, USA.
Emory University · USRegenstrief Institute · USUniversity of California, San Francisco · US

Funding

Reducing Racial Disparities in Access to Kidney Transplantation: the RaDIANT Regional StudyU01MD010611 · NIMHD · EMORY UNIVERSITY · PI PATZER, RACHEL E · 2016 to 2020
$2.8M
Improving Quality and Access to Early Steps in Kidney TransplantationR01DK122701 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI PASTAN, STEPHEN, PATZER, RACHEL E · 2019 to 2022
$2.5M
Early Access to Kidney Transplantation among Patients with Lupus NephritisF31DK135379 · NIDDK · EMORY UNIVERSITY · PI MCPHERSON, LAURA · 2023 to 2024
$71k
NIDDK NIH HHS F31 DK135379NIDDK NIH HHS R01 DK122701NIMHD NIH HHS U01 MD010611
6 · The paper itself

Abstract

objectiveFor the majority of patients with lupus nephritis-related end-stage kidney disease (LN-ESKD), kidney transplant is associated with better outcomes than dialysis. Access to kidney transplant requires an initial referral to a transplant center and medical evaluation prior to waitlisting. The study's objective was to examine access to these early steps in the kidney transplant process among patients with LN-ESKD.

methodsAdults who began treatment for ESKD in the Southeast, Northeast, New York, or Ohio River Valley U.S. regions from 1/1/2012 to 12/31/2019, followed through 6/30/2021, were identified from the United States Renal Data System. Referral and evaluation start data were collected from 28 of 48 transplant centers across these regions. The exposure was primary cause of ESKD (LN-ESKD vs other-ESKD). The outcomes were referral and evaluation start at a transplant center. Cox models quantified the association between LN-ESKD (vs other-ESKD) and referral and evaluation start.

resultsAmong 192,318 patients initiating treatment for ESKD, 0.4% had LN-ESKD. Over half (58%) of LN-ESKD patients were referred before study end, and among those referred, 66% started the evaluation. In adjusted analyses, patients with LN-ESKD were referred (HR: 1.09, 95% CI: 0.99, 1.19) and started the transplant evaluation (HR: 1.13, 95% CI: 1.00, 1.28) at a higher rate than patients with other-ESKD. Among referred patients with LN-ESKD, the median time from ESKD start to referral was 2.9 months (IQR: <1 to 11.7 months), which is similar to patients with other-ESKD (median 2.6 months, IQR: <1 to 8.8 months).

conclusionsAmong incident patients with ESKD, having a primary diagnosis of LN-ESKD versus other-ESKD is associated with higher rates of early transplant access outcomes. Despite this, patients with LN-ESKD (vs other-ESKD) are less likely to be preemptively referred (i.e., referred prior to ESKD start) for kidney transplant. While providers may no longer be delaying the early steps in the kidney transplantation process among this patient population, there is still room for improvement in the rates of preemptive referral. Access to kidney transplant referral prior to ESKD could result in increased transplant rates and better transplant outcomes for patients with LN-ESKD.

Indexed as

Kidney Failure, ChronicKidney TransplantationLupus Erythematosus, SystemicLupus NephritisAdultHumansKidneyReferral and ConsultationUnited StatesNephritisrenal lupussystemic lupus erythematosus

Identifiers

PMID38019182
PMCPMC10842868
OpenAlexW4389135228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.